PEGASTA 6ML INJ. PFS.

About

Pegasta 6ml Injection contains the active ingredient Pegfilgrastim, which belongs to the granulocyte colony-stimulating factor (G-CSF) class. It is FDA-approved to reduce the risk of febrile neutropenia—a condition characterized by fever or infection alongside a low white blood cell (WBC) count—and to shorten the duration of neutropenia caused by bone marrow-suppressing chemotherapy drugs. Additionally, it is used to improve survival rates in patients exposed to radiation therapy that may cause severe, life-threatening damage to the bone marrow. Pegfilgrastim works by stimulating blood-forming cells, promoting their multiplication and enhancing their function.

Pegfilgrastim is a protein produced using biotechnology in E. coli bacteria. It is part of the cytokine protein family and closely resembles the natural granulocyte-colony stimulating factor produced by the body. White blood cells are crucial for fighting infections, but chemotherapy often lowers their count, leaving the body vulnerable to infections.

Before starting treatment with this injection, inform your doctor if you have a history of liver disease, fever or infection, kidney or heart problems, or any family history of kidney disease. Avoid using this injection if you are allergic to pegfilgrastim, filgrastim, or any other ingredients in the formulation. Contact your doctor immediately if you experience symptoms such as pain in the upper left abdomen, shoulder pain, or breathing difficulties. The most commonly reported side effects include pain in the bones, arms, and legs.

Uses

• To prevent neutropenia (low white blood cell count) in patients undergoing chemotherapy:
  It helps stimulate the bone marrow to produce more neutrophils (a type of white blood cell) to reduce the risk of infection caused by chemotherapy.
• To treat severe chronic neutropenia:
  It can be used in conditions where the body does not produce enough neutrophils naturally.
• To aid recovery of neutrophil counts after bone marrow transplantation.
• To reduce the duration of neutropenia and the risk of febrile neutropenia in patients receiving cytotoxic chemotherapy for non-myeloid malignancies.

Directions for use

This medicine will be administered by your doctor or nurse. Please do not attempt to self-administer it.

Side effects

Alcohol - Consuming alcohol while using Pegasta 6ml Injection is unsafe. It is important to talk to your doctor for further guidance.
Pregnancy - Pegasta 6ml Injection should not be used during pregnancy, as it may cause birth defects. If you are pregnant or planning to become pregnant, consult your doctor before starting treatment.
Breastfeeding - Breastfeeding is not recommended during treatment with Pegasta 6ml Injection, as it may potentially harm the baby. Please consult your doctor before breastfeeding while on this medication.
Liver - It is not clear whether Pegasta 6ml Injection is safe for patients with liver disorders. Inform your physician if you have any liver problems before starting treatment.
Kidney - Pegasta 6ml Injection may affect kidney function in some cases. It is important to inform your doctor if you have any kidney problems before starting treatment, as close monitoring might be needed to avoid potential complications.

Disclaimer

Med E Hub is committed to delivering reliable, expert-reviewed information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.